Back to resultsThe Percentage of Cases of Acute Treatment With Allopurinol in Gout Patients
Primary Purpose
Gout
Status
Unknown status
Phase
Not Applicable
Locations
Israel
Study Type
Interventional
Intervention
Allopurinol
Sponsored by
About this trial
This is an interventional treatment trial for Gout
Eligibility Criteria
Inclusion Criteria:
- Gout patients
Exclusion Criteria:
- Pregnant women
- Chronic renal failure
- Patients with Allopurinal hypersensitivity
Sites / Locations
- Hillel Yaffe Medical Center
Arms of the Study
Arm 1
Arm Type
Other
Arm Label
Gout Patients
Arm Description
Allopurinol 100 mg-300mg/day as secondary treatment in gout patients
Outcomes
Primary Outcome Measures
Gout patients treated with Allopurinol
Retrospective identification through medical records of percentage of gout patients treated with Allopurinol
Secondary Outcome Measures
Patients with contraindication to Allopurinol
Retrospective identification through medical records of percentage of gout patients with contraindications to Allopurinol
Full Information
NCT ID
NCT03601260
First Posted
July 18, 2018
Last Updated
July 18, 2018
Sponsor
Hillel Yaffe Medical Center
1. Study Identification
Unique Protocol Identification Number
NCT03601260
Brief Title
The Percentage of Cases of Acute Treatment With Allopurinol in Gout Patients
Official Title
To Examine the Percentage of Cases of Acute Treatment With Allopurinol in Gout Patients as Secondary Treatment
Study Type
Interventional
2. Study Status
Record Verification Date
July 2018
Overall Recruitment Status
Unknown status
Study Start Date
August 2018 (Anticipated)
Primary Completion Date
December 2018 (Anticipated)
Study Completion Date
December 2018 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Hillel Yaffe Medical Center
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
The aim of the study is to determine the percentage of cases of acute treatment with Allopurinol in gout patients who have been previously treated.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Gout
7. Study Design
Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
700 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
Gout Patients
Arm Type
Other
Arm Description
Allopurinol 100 mg-300mg/day as secondary treatment in gout patients
Intervention Type
Drug
Intervention Name(s)
Allopurinol
Intervention Description
Treatment of gout patients by oral dosage of 100 mg-300mg/ day of Allopurinol
Primary Outcome Measure Information:
Title
Gout patients treated with Allopurinol
Description
Retrospective identification through medical records of percentage of gout patients treated with Allopurinol
Time Frame
Six months
Secondary Outcome Measure Information:
Title
Patients with contraindication to Allopurinol
Description
Retrospective identification through medical records of percentage of gout patients with contraindications to Allopurinol
Time Frame
Six months
10. Eligibility
Sex
All
Minimum Age & Unit of Time
25 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Gout patients
Exclusion Criteria:
Pregnant women
Chronic renal failure
Patients with Allopurinal hypersensitivity
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Fadi Khalaila, MD
Phone
972-52-3326629
Email
khalailaf@yahoo.com
Facility Information:
Facility Name
Hillel Yaffe Medical Center
City
Hadera
ZIP/Postal Code
38100
Country
Israel
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Fadi Khalaila, MD
Phone
972-52-3326629
Email
khalailaf@yahoo.com
12. IPD Sharing Statement
Plan to Share IPD
No
Learn more about this trial
The Percentage of Cases of Acute Treatment With Allopurinol in Gout Patients
We'll reach out to this number within 24 hrs